ANI Pharmaceuticals
ANIP
307 hedge funds and large institutions have $1.9B invested in ANI Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 119 increasing their positions, 89 reducing their positions, and 24 closing their positions.
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
34% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 89
9% more funds holding
Funds holding: 281 → 307 (+26)
6% more capital invested
Capital invested by funds: $1.8B → $1.9B (+$103M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.37% less ownership
Funds ownership: 104.38% → 101.01% (-3.4%)
95% less call options, than puts
Call options by funds: $811K | Put options by funds: $17.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
+$30.7M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$20.7M |
| 3 |
BlackRock
New York
|
+$16.9M |
| 4 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$15.8M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
+$10M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Goldentree Asset Management
New York
|
-$51.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$46.1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$16.1M |
| 4 |
SCM
Sio Capital Management
New York
|
-$13.5M |
| 5 |
FGP
Freestone Grove Partners
San Francisco,
California
|
-$12.3M |
ANIP Hedge Fund Activity: Q2 2026 in Review
307 of the 8,296 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2026, worth a combined $1.9B — up 5.7% from $1.8B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ANIP positions and 24 closed out — a net gain of 29 holders — while 119 added to existing stakes and 89 trimmed.
The largest buyer was American Century Companies, adding an estimated $30.7M. The largest seller was Goldentree Asset Management, exiting entirely with an estimated $51.3M sold.
- 307 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2026, up from 281 in Q1 2026.
- Funds reported $1.9B of ANI Pharmaceuticals stock for Q2 2026, up 5.7% quarter-over-quarter.
- 53 funds opened new ANI Pharmaceuticals positions in Q2 2026 and 24 closed out, a net change of +29 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2026 was American Century Companies, an estimated $30.7M added.
- The largest ANI Pharmaceuticals seller in Q2 2026 was Goldentree Asset Management, an estimated $51.3M sold.
Based on aggregated 13F filings for Q2 2026.